COPD
Conditions
Keywords
COPD, Triple Therapy, ICS, LABA, LAMA
Brief summary
The proposed study will evaluate (for newly diagnosed Chronic Obstructive Pulmonary Disease (COPD) patients)the time taken to prescription of triple therapy by aiming to answer these following research questions: 1. The percentage of patients prescribed triple therapy, and when they first started receiving triple therapy. 2. For patients prescribed triple therapy, the time taken to triple therapy from initial diagnosis of COPD. 3. The variation in treatment pathways. 4. The factors associated with time taken to triple therapy.
Detailed description
Triple therapy consists of long-acting beta agonist (LABA) + inhaled corticosteroids (ICS) + long-acting muscarinic antagonist (LAMA) and typically should be reserved for patients who have severe to very severe (FEV1 \<50%) COPD symptoms or for patients who have two or more exacerbations per year. However previous research from RiRL indicate that 50% of patients at GOLD stage II (moderate) receive ICS of which half were on triple therapy. To allow for multiple analysis regarding the factors that influence the likelihood of being prescribed triple therapy, a bespoke COPD dataset will be created to include: 1. Disease severity markers: 2. Confirmation of a COPD diagnosis at initial date of COPD diagnosis 3. Standard co-morbidities fields 4. Demographic fields This retrospective, observational study using data of COPD patients will assess treatment pathways (changes/step up) from initial date of COPD diagnosis with the prescription of triple therapy as the endpoint. Specific questions that will be asked are: 1. Does the percentage of COPD patients prescribed triple therapy vary dependent on time of initial date of COPD diagnosis? 2. Does the time taken to the prescription of triple therapy vary dependent on initial date of COPD diagnosis?
Interventions
None listed
Sponsors
Novartis Pharmaceuticals
Research in Real-Life Ltd
Study design
Observational model
COHORT
Time perspective
RETROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
40 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Aged ≥40 years at initial date of COPD diagnosis * COPD diagnosis with Quality Outcome Framework (QoF) approved read code * has spirometry data supportive of a COPD diagnosis in the 5 years around initial date diagnosis of COPD (FEV1 % predicted) * Patient has one year of data prior to initial date of COPD diagnosis * Patient has a minimum of two years of data post initial date of COPD diagnosi
Exclusion criteria
* Patients whose initial date of COPD diagnosis is before 1997
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Triple Therapy Status | 1 year | The proportion of patients prescribed triple therapy and whether they were prescribed it prior to, at, or after initial date of COPD diagnosis. |
| Initial date of COPD diagnosis | 1 year | The date that patients were initially diagnosed with COPD. Categorised into cohorts- 1997-2001, 2002-2006, 2007-2010. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| COPD patient group | 1 year | Patients COPD patient group, calculated by GOLD A, B, C, D criteria dependent on symptoms and risk of patient. |
| COPD exacerbations (Clinical experience based) | 1 year | Number of the following: (i) Asthma/copd-related\*: a. Hospital attendance / admissions OR b. A&E attendance OR (ii) GP consultations for lower respiratory related tract infections |
| Lung function grade | 1 year | Patient lung function grade, calculated by GOLD I, II, III, IV criteria. |
| BMI | 1 year | Patient BMI class |
| COPD co-morbidities | 1 year | COPD co-morbidities are identified via Read codes that are recorded at any time. Co-morbidities are: GERD, Rhinitis, Heart Failure, Ischaemic Heart Disease, Diabetes, Osteoporosis, Chronic Renal Failure, Chronic Kidney Disease and Anxiety-Depression |
| Smoking Status | 1 year | Patient smoking status, taken from routine and questionnaire data |
| Asthma Diagnosis | 1 year | Proportion of patients with a co-morbid asthma diagnosis |
Countries
United Kingdom
Outcome results
None listed